News

Vertex Pharmaceuticals (NASDAQ: VRTX) transformed the world of cystic fibrosis (CF) treatment when it launched its first product for the disease 12 years ago. Since then, it's built a CF treatment

Investing in equity markets is a reliable, wealth-growing strategy. In the past 33 years, the S&P 500's average annual return is about 10.6%. It's hard to find a return much better than that

With Vertex Pharmaceuticals (NASDAQ: VRTX) announcing on June 21 that its therapy VX-880 helped nearly all of the patients with diabetes in a clinical trial to reduce or eliminate their need for

When a company obtains positive news from the Food and Drug Administration (FDA), such as the approval of a treatment or a label expansion, it can mark a milestone for the business and lead to

A few years ago, Eli Lilly (NYSE: LLY) was far from the hottest stock in the biopharmaceutical world. But times have changed. Today, Lilly ranks as the biggest healthcare company in the world. It

Most investors know the phrase "buy low, sell high." It's a fine piece of investing wisdom, but it isn't as straightforward as it seems. Even a company whose shares are performing well can be

ResMed has had the market on sleep apnea cornered for a while, but new weight loss drugs might be creeping in. In this podcast, we look at what could change based on recent studies and some other

Pfizer (NYSE: PFE) can be a polarizing stock to own right now. Its future remains hazy given that it is facing some troubling patent cliffs and revenue from its COVID-19 vaccine is dwindling. But at

It's been a big year for most stocks, with the S&P 500 index up about 24% over the past 12 months. A rising market is wonderful for the stocks already in your portfolio, but finding new investment

Most retirees prefer low turnover in their investment portfolios. The less drama, the better. That way, they can focus on doing what they enjoy instead of worrying about their investments.

Three

If you're an investor who doesn't already have access to billions in capital, you could probably learn a few things from the folks who do. Luckily, keeping tabs on the world's most successful

If there is one thing income investors like more than regular dividend payouts, it's regular and growing dividend payouts. Not every corporation can offer that, of course. Some will eventually

The stock market has its ups and downs -- and if you stay invested for decades, you will likely experience your fair share of both bull and bear markets. At the same time, by investing in a diverse

Shares of pharmaceutical giant Pfizer (NYSE: PFE) have been steadily sliding lower over the past year as revenue and profits from the pandemic's vaccine boom dry up. Today, the stock has seemingly

Believe it or not, we're nearly halfway through this decade. The healthcare sector could be in store for monumental changes over the next few years.

These changes should present great opportunities

It's no secret why Pfizer (NYSE: PFE) stock has been struggling this year. Investors are worried about how well the company will be able to do in light of waning demand for its COVID-19 vaccine and

The benchmark S&P 500 index is up an exciting 25.8% over the past year, but many of its components haven't participated in the gains. Nvidia and other members of the "Magnificent Seven" have been

The S&P 500 is soaring as this bull market roars on, but some stocks, even those that have rebounded in recent times, still are trading at much lower levels than in the past. In fact, two stocks

When one player stumbles in a high-stakes competition, it's often to the glee of the other contenders. In mid-June, Pfizer's (NYSE: PFE) gene-therapy candidate to treat Duchenne muscular dystrophy

It's obvious why Pfizer (NYSE: PFE) is eager to produce a medicine like Wegovy, Novo Nordisk's (NYSE: NVO) smash-hit obesity therapy that's essentially a slightly different version of its type 2

If you're looking to pump up your passive income stream, there are a handful of high-yield dividend stocks that deserve your attention. AbbVie (NYSE: ABBV), Ares Capital (NASDAQ: ARCC), and Realty

Vertex Pharmaceuticals (NASDAQ: VRTX) recently excited the medical community with clinical trial results from an experimental diabetes treatment it's developing. In a nutshell, it looks like a